Insomnia Market Snapshot: Generics May Keep Drug Makers Up At Night
Executive Summary
A new wave of sleep aids could soon be on the market, drugs designed to improve sleep quality and with fewer side effects than existing drugs. That's good news for the legions of insomnia sufferers turned off by existing prescription sedative/hypnotics
You may also be interested in...
Bright-Eyed And Bushy Tailed: Purdue Launches Intermezzo
Purdue Pharma launched Transcept Pharmaceutical’s Intermezzo, a low-dose sublingual tablet version of the generic sleep aid zolpidem, for middle-of-the-night awakenings April 5. Priced at a wholesale acquisition cost of $6.45 per tablet, the drug could face an uphill commercial road competing against generics.
Merck On Track To File Novel Sleep Aid Suvorexant In 2012
Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.
Merck On Track To File Novel Sleep Aid Suvorexant In 2012
Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.